Brad Hoppmann at Uncommon Wisdom Daily is pitching his “entry level” Cash Flow Kings newsletter by promising two “secret” investments that will help you profit from the “Fall of the Wall” … so what’s he talking about? Well, the “Wall” is, of course, his metaphor for what a lot of folks, particularly the small investors […]
Articles
- Most Relevant
- Most Recent
I’m a little late getting going today… I’d like to say that I’m jet-lagged, but really I’m just email-lagged as I try to dig through the few days of messages that I missed in my brief foray to the Emerald Isle over the past few days (which was fantastic, by the way, thanks for asking). […]
Bonner & Partners, which is yet another publisher subsidiary of Bill Bonner’s Agora empire, has a new teaser pitch out for Jeff Brown’s Exponential Tech Investor — and what caught the eye of Gumshoe readers was the headline, in the ad from Bonner’s Managing Director Amber Lee Mason, that promises huge gains from a “$39 […]
Louis Navellier has been around for far longer than most of the newsletter pundits, and his quantitative system has proven itself to be pretty good on average for long periods of time (though it also has taken big hits during rapid market collapses, of course) — we write about his teaser picks from time to […]
Never does this get boring. Every time thing seem to run a little dry here at Gumshoe HQ, and the reservoir of hypetastic teasers dips a little bit below the intake pipe … well, the flood comes again, regular as the rains (if not quite as seasonal). That’s how it’s been for a thousand teaser […]
I’ve been seeing a new ad from Amber Mason for the DailyWealth Trader service in the last week or so — it’s all about a special way to earn dividends, but to do so much more quickly. What’s she talking about? Well, I expect we’ll find that this is yet another option-selling pitch (several of […]
In case you’ve been living under a rock, the hot IPO news this year is that both Lyft and Uber are going public (along with other mega-IPOs Pinterest (PINS) and, probably, Palantir) — Lyft (LYFT) is already trading and generated a lot of excitement on the first day, though came back down sharply almost immediately, […]
Most of us might not have heard of Georges Yared a year ago, but any individual investor with an email address will have a hard time avoiding him now — his is one of the latest investment newsletters launched by InvestorPlace Media, the folks who make sure we all know about newsletter advisers Robert Hsu, […]
Bitterness over the financial bailouts seems to have waned a bit, but there’s certainly a strong vein of anger to mine … and that’s exactly what copywriters are paid to do. This time, it’s in an ad for Jim Nelson’s Lifetime Income Report — and this is the investment idea he’s got for you: “This […]
The Most Valuable Pill in the World will double your moneyStansberry research is touting a biotech pick that will cure a disease that kills 1 out of 4 people. What is it?
Teaser from https://www.angelnexus.com/o/web/315108 ” Jeff Bezos, Peter Thiel, and the Rockefellers are betting a colossal nine figures on: The #1 Stock of This Generation Investors who get in on this tiny $5 stock… Stand to transform every $500 invested into $1.5 million.” Any ideas???
Any one have an idea as to what stock Ray Blanco is referring to in his ”Breakthrough Technology Alert” teaser?
Which company? This is not Ozempic, Advil, or vitamin D… It’s an entirely new class of medicine that could earn you an absolute FORTUNE. Because not only can it make you smarter, make you stronger, and extend your life span by as much as 20 years… It’s also the most profitable drug in human history… […]
Newsletter copywriters are no different from other marketers: they will do whatever it takes to get attention by playing off of something or someone that has celebrity or notoriety. In the past that’s meant implying that some big celebrity investor has a connection to a “secret” stock or technique, or that someone high up in […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. Enjoy!] It could be the premise of a tawdry unrated movie that teenage boys sneak glimpses of on Netflix when they’re home alone. […]
I’m still able to generate some enthusiasm about specific stocks that I think are appealing enough to buy at these prices… but I find it very hard to be optimistic in a macro sense right now, it really feels to me as though the market is whistling past the graveyard and being far too sanguine […]
I’ve got a handful of updates for you, including one on a stock that I bought yesterday and a few other notes about recent quarterly reports from stocks I follow, but first … a teaser to solve … When I wrote about Marc Lichtenfeld’s pitch for “Spread Trusts” yesterday, I promised to also try to […]
In light of a interview I watched tonight of Steve Sjuggerud’s forecast on the Yuan becoming the next IMR, I found some challenges to Steve’s interview and would like a comment or rebuttal. These challenges were in the Wall Street Journal: ”To be sure, even if the yuan is recognized by the IMF as a […]
Crocker is a comanager at the Metropolitan Capital hedge fund. His big question is figuring out Groupe Fnac — European retailer and ticketing business (the “Ticketmaster of France). It’s priced as if disaster is around the corner, and it has a huge cash balance. Stores are mainly in France, Spain and Portugal, a few others. […]
Here’s what I’m trying to avoid: Predicting the direction of the markets because of my deep understanding of US-China trade dynamics. Every time I read an article that asserts “China trade deal more likely because of Bolton firing” or something like that, I throw up in my mouth a little bit. The market is way […]
I’ve had a bunch of readers asking me to look at the ads for Chris Mayer’s new service, so that’s the plan today. We don’t usually see ads for newsletters that cite Stock Gumshoe, so that also helped catch my eye when I was browsing ads and deciding which teaser pitch to cover recently — […]
Regular investors are getting interested in gold again, after the big run it had in the first half of this year… and many of us also remember the ludicrous returns that many folks got from buying bitcoin early on… so it’s only natural that this ad puts our greed receptors into overdrive: “The time to […]
This ad has been rolling for a week or so, and a group of Gumshoe readers have already been discussing it and trying to figure out exactly what the Stansberry folks are talking about… but there are lots of questions still coming over the transom here at Castle Gumshoe, so let’s take a look. The […]
I got a few requests to take a look at the “better restaurant stock” that Timothy Lutts of Cabot alluded to in his recent article about Chipotle (CMG), and one of those readers pointed out that one of the other stocks that Cabot has been teasing, LeMaitre Vascular (LMAT), “has been looking good” … so […]
Nick Giambruno is helming the Crisis Investing letter for Casey Research now, which must come with a fairly high degree of attention because Doug Casey really made his name with his bestselling book of the same name in the late 1970s (later revised a couple times). And after all this time you know what you’re […]
Previously thought about starting this thread based on population increase, scarcity and listening to Arch1 and HendrixNuzzles. So here it is. Share your best ideas, news, equities and thoughts. Best2All ~ Ben
Another month, another big pitch about a biotech stock with a great “P-Value Indicator” from Ernie Tremblay, all in an ad for his Biotech Insider Alert. Should we pay attention? Well, we can hardly avoid noticing it — we’re being battered about the head and neck with the constant email fusillade from Tremblay’s publisher and […]
So, I’ve been following Aralez (ARLZ) for years. It’s my favorite drug trade. This company has a history of producing valuable drugs. Once they develop a drug, their strategy is to sell the licensing to other companies that produce and market the drugs, and pay ARLZ huge royalties with very attractive minimums, essentially make ARLZ […]
[ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All of his past […]
There’s no shortage of long-winded teaser pitches to sit through today, but we haven’t looked at an energy teaser in a while… so let’s check out this latest spiel from Christian DeHaemer about “Energy Megafields” and see if the Thinkolator can identify some interesting oil and gas stocks for you to research. We’ve looked at […]
[Ed. Note: Dr. KSS writes about medicine biotech stocks for the Gumshoe Irregulars. He chooses his own topics, and his words and opinions are his own. Visit his Stock Gumshoe page for his past articles and most recent comments.] Assessing biotechnology stocks involves use of lots of mental microscopes and magnifying lenses. But the task […]
This discussion provides the current and future of of Li, G, NAM; H2O and more… After Fukushima REBECCA JOHNSON 24 March 2011 https://www.opendemocracy.net/5050/rebecca-johnson/after-fukushima LONG TSX-V: GGG $0.25 OTCQB: $GPHBF $0.19, July 28, 2016 Graphene 3D Lab Introduces New Type of Single Layer Graphene Material: http://www.graphene3dlab.com/s/news.asp?ReportID=757543&_Type=News&_Title=Graphene-3D-Lab-Introduces-New-Type-of-Single-Layer-Graphene-Material $GLFN – http://galenfeha.com/ and #Gummune … Author: arch1 Comment: http://www.stockgumshoe.com/2016/03/microblog-club-house-for-the-discussion-of-religion-politics-and-other-unmentionables-volume-5/comment-page-17/#comment-4886050 […]
Ethereum: The Battle Of The Chains There is a growing “battle of the chains” in the Ethereum world…. the latest, Kraken, opened ETC trading on July 27th after previously saying it would not support it. Currently, ETC market cap is about $150m – which for a chain that was supposed to have shriveled and died […]
Bonner & Partners, which is yet another publisher subsidiary of Bill Bonner’s Agora empire, has a new teaser pitch out for Jeff Brown’s Exponential Tech Investor — and what caught the eye of Gumshoe readers was the headline, in the ad from Bonner’s Managing Director Amber Lee Mason, that promises huge gains from a “$39 […]
I may have to add a little dose of guessing to the Thinkolator results on this one, but we’ve had a few folks asking “who beat Amazon?” of late, thanks to this latest Motley Fool ad, so I’m going to give it a try. The ad is for the Motley Fool’s flagship Stock Advisor service, […]
Today I’m breaking up our Friday File into two segments, which many of you have noted that you prefer — one part is a teaser pitch solution, the other is an update on a few stocks that I own and/or have suggested to the Irregulars. The teaser pitch is a look into Cabot’s “Stock of […]
Newsletter copywriters are no different from other marketers: they will do whatever it takes to get attention by playing off of something or someone that has celebrity or notoriety. In the past that’s meant implying that some big celebrity investor has a connection to a “secret” stock or technique, or that someone high up in […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, writes for us a couple times a month on medicine and health issues. He is not a physician, but explains the science and the data well, and helps provide some background understanding and perspective that often benefits both investors and folks who are attentive […]
Good title for an article, right? I’ve realized, after getting a few questions, that some Gumshoe readers are interested in a few of my less liquid, more levered, or riskier investments, the ones (like options and warrants) that I don’t really talk much about when I post my personal portfolio comments (except when there’s a […]
David Gardner at the Motley Fool is usually the “growth” guy — he’s the one who has most famously grabbed on to “story” stocks when they were crazy expensive but had big growth potential, and held on for gains of several thousand percent (Netflix, Priceline, etc.). So it caught my eye that he’s recommending a […]